FDA Approves Lutetium Lu 177 Dotatate for Pediatric SSTR+ GEP-NETs
The FDA has approved lutetium Lu 177 dotatate for pediatric patients 12 years of age and older with SSTR–positive GEP-NETs.
Source: onclive.com
📰 Gep Nets News
Gep Nets News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Gep Nets. Real-time updates on events, politics, business and more.
177Lu-Dotatate Prolongs PFS vs High-Dose Octreotide in GEP-NETs
Lutetium Lu 177 dotatate plus octreotide significantly improved PFS vs high-dose octreotide in patients with gastroenteropancreatic neuroendocrine tumors.
Advanced Accelerator 177lu Dotatate Gep Nets Gastroenteropancreatic Neuroendocrine Tumors Neuroendocrine Tumors Lutetium Lu 177 Dotatate
Source: onclive.com
FDA Accepts Filing of Abbreviated NDA for Generic Lutathera in GEP-NETs
The FDA has accepted the filing of an abbreviated new drug application (ANDA) for Lutetium Lu 177 Dotatate, a generic version of lutetium Lu 177 dotatate indicated for the treatment of patients with somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors in adults.
United States Joe Mccann Mary Anne Heino University Health Network Anne Heino Gastrointestinal Cancer
Source: onclive.com
ITM to Present Phase III COMPOSE Poster and Host Satellite
Garching / Munich, March 16, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical theranostics company, today announced that the...
United States Uppsala Lan Comunidad Autonoma De Cataluna Jaume Capdevila Ben Orzelek Julia Hofmann Svenja
Source: globenewswire.com